Image Guided Surgery for Margin Assessment of Head and Neck Cancer Using Cetuximab-IRDye800CW cONjugate

NCT03134846 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

79

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Squamous Cell Carcinoma
Margin Assessment

Interventions

DRUG: Cetuximab-IRDye800CW

Sponsor

University Medical Center Groningen

Collaborators

[object Object]
[object Object]